Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook. Basic financial performance and product development updates are promising, but ongoing litigation and vague responses in the Q&A raise concerns. The market strategy and shareholder return plan lack clarity, and there's no strong catalyst like a new partnership or record revenue. With no market cap provided, it's assumed to be a mid-cap stock, leading to a neutral prediction as the positive and negative factors balance each other.
Key Financial Performance
Cash and Cash Equivalents $4.4 billion, no year-over-year change mentioned, strong capital position to support pipeline profitability and expansion.
Loss from Continuing Operations $166 million net of tax, no year-over-year change mentioned, straightforward financial quarter.
Share Buybacks Significant share buybacks over the last 18 months, no specific figures or year-over-year change mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Brepocitinib in DM: Phase III data for brepocitinib in dermatomyositis (DM) showed success on all 10 ranked endpoints. The NDA filing is planned for the first half of next year, potentially making it the first novel oral therapeutic in DM.
Batoclimab in Graves' Disease: Data from the durable remission portion of the Graves' disease trial demonstrated disease-modifying potential. Patients showed sustained response even after being off the drug for six months.
IMVT-1402: Initiated potentially registrational trials in multiple indications, including Graves', myasthenia gravis, CIDP, difficult-to-treat RA, and Sjögren's, as well as a proof-of-concept trial in CLE.
Graves' Disease Market: Significant unmet need with 330,000 U.S. patients unable to get well-controlled. Shift away from ablation procedures has increased demand for medical therapies.
Dermatomyositis Market: 75% of patients rely on steroids or ISTs, with limited therapeutic options. Brepocitinib could address this underserved market.
Capital Position: Strong financial position with $4.4 billion in cash and cash equivalents, supporting pipeline profitability and potential capital returns.
LNP Litigation: Favorable Markman ruling in the Pfizer case and ongoing progress in litigation with Moderna, with a trial scheduled for March 2026.
Pipeline Expansion: Focus on advancing late-stage pipeline with 11 potentially registrational trials and multiple blockbuster indications.
Investor Engagement: Investor Day scheduled for December 11, 2025, to discuss future plans and progress.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is in the process of submitting an NDA for brepocitinib, with the submission planned for the first half of next year. Regulatory approval processes are inherently uncertain and could delay or impact the launch of the product.
Competitive Landscape: The evolving competitive landscape in TED and Graves' disease has led the company to delay reporting top-line data for TED until the first half of next year. This indicates potential challenges in differentiating their product in a competitive market.
Pipeline Execution Risks: The company has a stacked pipeline with multiple registrational trials and launches planned over the next 36 months. Managing these simultaneous initiatives poses risks related to resource allocation, operational execution, and meeting timelines.
Litigation Risks: The company is involved in ongoing LNP litigation with Moderna and Pfizer. While there has been a favorable Markman ruling in the Pfizer case, the outcomes of these legal proceedings remain uncertain and could have financial or operational implications.
Economic and Financial Risks: Although the company has a strong cash position of $4.4 billion, the significant investment required to advance its pipeline to profitability and support potential capital returns could strain financial resources if unexpected costs arise or revenue generation is delayed.
Market Adoption Risks: The company is targeting diseases with significant unmet needs, such as DM and Graves' disease. However, market adoption of new therapies can be unpredictable, especially in underserved or niche markets.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
NDA filing for brepocitinib in DM: The NDA filing for brepocitinib in dermatomyositis (DM) is planned for the first half of 2026. If approved, it will be the first novel oral therapeutic in DM.
Immunovant's IMVT-1402 trials: Immunovant has initiated potentially registrational trials in Graves' disease, myasthenia gravis, CIDP, difficult-to-treat rheumatoid arthritis (RA), and Sjögren's syndrome, as well as a proof-of-concept trial in CLE.
Genevant litigation updates: The jury trial in the Moderna case is scheduled for March 2026, with continued progress in LNP litigation.
Capital position and pipeline funding: The company has $4.4 billion in cash and cash equivalents, which is expected to fund the current pipeline to profitability, support pipeline expansion, and allow for potential additional capital returns.
Late-stage pipeline and upcoming launches: The company has 11 potentially registrational trials in indications with blockbuster potential. Multiple launches are anticipated in the next 36 months, including brepocitinib in DM and NIU, followed by IMVT-1402 in Graves' disease and other indications.
Graves' disease program for batoclimab: The program demonstrated disease-modifying potential, with 17 out of 21 patients remaining responders to therapy six months off drug. The next data readouts are expected in 2027.
TED study update: The TED study is on track to conclude this year, but top-line data will likely be reported in the first half of next year alongside data from a second study.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: No specific mention of dividends or a dividend program was made in the transcript.
Share Buyback Program: The company has authorized a $500 million share buyback program. This is part of their capital return strategy, supported by their strong financial position with $4.4 billion in cash and cash equivalents. The share count reflects significant buybacks conducted over the last 18 months.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What should we watch next with respect to Pfizer litigation, specifically in international markets and the U.S.?
A:The CEO mentioned that it is tough to comment on ongoing litigation and had no updates on the timing of international cases. He noted that there should be a scheduling process for the Pfizer case underway, and they hope to learn more about the timeline, including a trial date, in the near future.
Q:How does the company feel about argenx stepping into Graves' disease, and does it impact their strategy for 1402?
A:The CEO acknowledged the competitive landscape in Graves' disease and expressed confidence in their higher-dose batoclimab data, which showed significant benefits. He emphasized the large patient population and noted that competition validates their strategy. He also praised argenx as a formidable company.
Q:What should investors expect from the upcoming Investor Day?
A:The CEO described it as a moment of transformation for the business, aiming to tell their story fully and highlight the commercial and patient need perspectives. He hinted at potential updates or new information but did not reveal specifics.
Q:Can the remission data in Graves' disease be linked to starting on high-dose batoclimab?
A:The CEO stated that remission is about TRAbs normalization and deeper IgG reductions. He highlighted the speed and depth of responses in their trial but avoided detailed comments due to the competitive landscape.
Q:What are the CEO's thoughts on the Moderna litigation and the U.S. government's involvement in vaccine distribution?
A:The CEO explained that the issue of government involvement is ultimately up to the judge. He provided context on the magnitude of the damages claimed, noting that less than half of Moderna's U.S. sales are in question. He emphasized their strong case but deferred to the judge's decision.
Q:What is the company's perspective on the Sjögren's disease market opportunity and differentiation of FcRns?
A:The CEO expressed excitement about the large patient population and unmet need. He noted that FcRns have shown competitive data and aim to differentiate through deeper IgG suppression. He also mentioned their goal to launch close to first-in-class.
Q:What is the update on business development and pipeline expansion?
A:The CEO stated that they remain well-capitalized and excited about pipeline expansion. They are focused on indication expansion for existing programs and are exploring opportunities that align with their scale and strategy.
Q:How does the company view the competitive landscape in Graves' disease and sequencing decisions?
A:The CEO acknowledged the competitive intensity but expressed confidence in their FcRn mechanism and timing. He highlighted the safety and well-tolerated profile of FcRns and their suitability for Graves' disease. He also noted that increased activity in the space benefits everyone.
Q:What is the company's confidence in translating Pulmovant data from PAH to PH-ILD?
A:The CEO expressed cautious optimism, noting that PVRs generally translate well between indications. He highlighted the 38% PVR reduction in pulmonary hypertension and the potential for significant benefit in PH-ILD.
Q:What is the status of overseas trials in the Moderna litigation?
A:The CEO mentioned ongoing actions in Europe, Canada, Japan, and other jurisdictions. He noted that some European jurisdictions move quickly, and initial decisions could be possible in 2026.
Q:What are the expectations for TED data and its impact on development strategy?
A:The CEO emphasized the high competitive bar in TED and the need for data that aligns with the competitive landscape. He also highlighted the potential insights into hyperthyroid Graves' patients and the interaction between Graves' and TED.
Q:How does the company plan to approach the TED and Graves' markets with 1402 and batoclimab?
A:The CEO noted that the TED and Graves' markets have different call points and stages of disease. He emphasized the larger Graves' population and their focus on upstream treatment. He deferred further comments until TED data is available.
Q:What are the plans for brepo in terms of indications and competitive landscape?
A:The CEO highlighted the strong data in DM and the potential for market-defining opportunities. He acknowledged the competitive landscape but emphasized their multiyear head start and the broad applicability of brepo.
Q:What is the company's perspective on the DM launch and its cadence?
A:The CEO noted the high unmet need in DM and the lack of recent novel therapies. He emphasized the large market opportunity and their cautious approach to launch speed, focusing on long-term trajectory.
Q:How does the company view the Graves' disease opportunity compared to MG for FcRns?
A:The CEO highlighted the large number of uncontrolled Graves' patients and the opportunity to make a meaningful difference. He deferred detailed comments to the upcoming Investor Day.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or used vague language in several instances: 1. Pfizer litigation timing in international markets was not addressed clearly. 2. Specific expectations for the Investor Day were not disclosed. 3. Detailed insights into remission data in Graves' disease were avoided due to competitive concerns. 4. The CEO deferred comments on the TED and Graves' market strategy until TED data is available. 5. No specific analogs or detailed expectations were provided for the DM launch cadence. 6. The CEO avoided commenting on the approvability of competitors' mechanisms in TED.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Officer
IR website
Instructions today
Officer Platforms
Platforms today
conference speaker
day Instructions
result today
speaker Chief
today CEO
today conference
update IR
website wwwinvestorroivantcom
wwwinvestorroivantcom slide
ROIV Transcript
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Neutral5-29
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
ROIV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
